title: New biologic agents for the treatment of gynecologic cancers.
abstract: The discovery of new biologic targeted agents and appropriately matching them to specific gynecologic tumor types either based on histology or the genetic make-up of the cancer is an exciting new chapter in the treatment of gynecologic malignancies. Therapeutic targets of multiple pathways are currently in study, and combinations with chemotherapy as well as combinations of pathway inhibitors are currently in development.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Neil
authors.initials: N
authors.lastname: Horowitz
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D058973:Folate Receptors, GPI-Anchored / Q000037:antagonists & inhibitors; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D058973:Folate Receptors, GPI-Anchored; D053823:Hedgehog Proteins; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D066246:ErbB Receptors; D051057:Proto-Oncogene Proteins c-akt